DK0977560T3 - Ibuprofen Thioesters as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators (CoA Thioesters of Arylpropionic Acids, Arylic Acids and Salicylates as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators) - Google Patents

Ibuprofen Thioesters as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators (CoA Thioesters of Arylpropionic Acids, Arylic Acids and Salicylates as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators)

Info

Publication number
DK0977560T3
DK0977560T3 DK98921471T DK98921471T DK0977560T3 DK 0977560 T3 DK0977560 T3 DK 0977560T3 DK 98921471 T DK98921471 T DK 98921471T DK 98921471 T DK98921471 T DK 98921471T DK 0977560 T3 DK0977560 T3 DK 0977560T3
Authority
DK
Denmark
Prior art keywords
kappab
inflammation
inhibitors
thioesters
acids
Prior art date
Application number
DK98921471T
Other languages
Danish (da)
Inventor
Holger Bang
Kay Brune
Gerd Geisslinger
Nicole Scheuren
Andreas Pahl
Werner Neupert
Original Assignee
Paz Arzneimittelentwicklung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paz Arzneimittelentwicklung filed Critical Paz Arzneimittelentwicklung
Application granted granted Critical
Publication of DK0977560T3 publication Critical patent/DK0977560T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to medicaments containing Co-A thioesters of arylpropionic acids, arylacetic acids or acetylsalicylates, R-ibuprofen or ibuprofen racemates with up to 49 % S-ibuprofen or derivatives of the above-mentioned compounds, which are metabolized in an analog manner in the organism. According to the invention, said medicaments are used to indicate acute and/or chronic pain and all types of inflammations and to treat all other symptoms of inflammatory processes.
DK98921471T 1997-04-21 1998-04-20 Ibuprofen Thioesters as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators (CoA Thioesters of Arylpropionic Acids, Arylic Acids and Salicylates as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators) DK0977560T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19716713A DE19716713A1 (en) 1997-04-21 1997-04-21 Medicines containing ibuprofenthioester as inhibitors of Nf-kappaB-dependent formation of mediators of inflammation and pain
EP98921471A EP0977560B1 (en) 1997-04-21 1998-04-20 IBUPROFEN THIOESTERS AS INHIBITORS OF Nf-kappaB-DEPENDENT PAIN AND INFLAMMATION MEDIATOR FORMATION
PCT/EP1998/002318 WO1998047502A1 (en) 1997-04-21 1998-04-20 IBUPROFEN THIOESTERS AS INHIBITORS OF Nf-λB-DEPENDENT PAIN AND INFLAMMATION MEDIATOR FORMATION

Publications (1)

Publication Number Publication Date
DK0977560T3 true DK0977560T3 (en) 2004-11-01

Family

ID=7827221

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98921471T DK0977560T3 (en) 1997-04-21 1998-04-20 Ibuprofen Thioesters as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators (CoA Thioesters of Arylpropionic Acids, Arylic Acids and Salicylates as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators)

Country Status (10)

Country Link
EP (1) EP0977560B1 (en)
JP (1) JP2001521539A (en)
AT (1) ATE270100T1 (en)
CA (1) CA2287501A1 (en)
DE (2) DE19716713A1 (en)
DK (1) DK0977560T3 (en)
ES (1) ES2219889T3 (en)
PT (1) PT977560E (en)
RU (1) RU2204388C2 (en)
WO (1) WO1998047502A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
DE19907895A1 (en) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Use of R-arylpropionic acids for the production of medicaments for the treatment of diseases in humans and animals which can be influenced therapeutically by inhibiting the activation of NF-kB
DE10047319A1 (en) 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Use of R-arylpropionic acids for the production of medicaments for the treatment of diseases which can be therapeutically influenced by inhibiting the activation of the nuclear transcription factor AP-1
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
RU2423379C2 (en) 2005-01-20 2011-07-10 Байомарк Фармасьютикалз, Лтд. Mucin hypersecretion inhibitors and methods of application thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
WO2008010025A1 (en) * 2006-07-18 2008-01-24 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
DK2053915T3 (en) 2006-07-26 2014-06-30 Biomarck Pharmaceuticals Ltd PEPTIDES TO REDUCE INFLAMMATORY MEDIATOR RELEASE
PL2170826T3 (en) 2007-06-04 2022-09-05 Techfields Inc Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
CA3213470A1 (en) 2008-12-04 2010-06-10 Chongxi Yu High penetration compositions and their applications
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
CA2752849C (en) 2009-07-24 2014-07-08 Bernd G. Seigfried Liquid compositions capable of foaming and including active agents, and methods for making or developing same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213301B (en) * 1986-07-14 1989-12-20 Zambon Spa COMPOSITIONS FOR THE TREATMENT OF SYNDROMES FROM ISCHEMIA AND REPERFUSION
GB8715476D0 (en) * 1987-07-01 1987-08-05 Shell Int Research Preparation of ibuprofen
DE4140179C2 (en) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Acute form for a drug containing ibuprofen
DE59209706D1 (en) * 1992-12-01 1999-07-08 Spirig Ag Medicines containing S (+) - ibuprofen
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
US6255347B1 (en) * 1996-06-21 2001-07-03 Advanced Research And Technology Institute Methods and compositions comprising R-ibuprofen

Also Published As

Publication number Publication date
ES2219889T3 (en) 2004-12-01
EP0977560A1 (en) 2000-02-09
CA2287501A1 (en) 1998-10-29
PT977560E (en) 2004-10-29
WO1998047502A1 (en) 1998-10-29
DE59811642D1 (en) 2004-08-05
JP2001521539A (en) 2001-11-06
DE19716713A1 (en) 1998-10-22
EP0977560B1 (en) 2004-06-30
ATE270100T1 (en) 2004-07-15
RU2204388C2 (en) 2003-05-20

Similar Documents

Publication Publication Date Title
DK0977560T3 (en) Ibuprofen Thioesters as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators (CoA Thioesters of Arylpropionic Acids, Arylic Acids and Salicylates as Inhibitors of the Nf-kappaB-dependent Formation of Inflammation and Pain Mediators)
BR0112073A (en) Therapeutic Combinations of Fatty Acids
DE69805846D1 (en) USE OF 3-BENZOYLPHENYL ACETIC ACIDS, THEIR ESTERS OR AMIDES FOR THE TREATMENT OF GLC1A GLAUCOMA
DE69720787D1 (en) PHARMACEUTICAL PREPARATION CONTAINING EICOSAPENTIC ACID AND / OR STEARIDONIC ACID
ES2099022B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SALTS OF ACID S (+) - 2- (4-ISOBUTYLPHENYL) PROPIONIC WITH BASIC AMINO ACIDS.
AR064895A2 (en) PHARMACEUTICAL COMPOSITION ANHIDRA FOR THE TREATMENT OF HISTAMINE INDUCED DISORDERS
DE60000133T2 (en) ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR SEASONS
RU99124628A (en) IBUPROPHENE TRIOESTER AS AN INHIBITOR DEPENDING ON NF-KB EDUCATION OF MEDIATORS OF INFLAMMATION AND PAIN
FI863976A (en) THERAPEUTIC COMPOSITION.
ES2194003T3 (en) HUPERZINA TO RACEMICA.
IT1187687B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE INGREDIENTS FLAVANOLIGNANI AND PHOSPHOLIPIDS
PT825857E (en) UTILIZATION OF GABAPENTINE AND ITS DERIVATIVES IN THE TREATMENT OF MANIAC AND BIPOLAR DISTURBACTIONS
DK0498144T3 (en) Use of acetyl L-carnitine in the therapeutic treatment of coma
NO996468L (en) Use of gaba analogues such as gabapentin in the manufacture of a medicament for the treatment of inflammatory diseases
DE60313998D1 (en) PAIN-FREE INJECTION PREPARATIONS OF 2-ARYLPROPIONIC ACID SALTS
IT1254314B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ACYL-CARNITINE ASSOCIATION WITH ACE-INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
NO932843L (en) Pharmaceutical preparations
IS6284A (en) Treatment of migraine by administering alpha-lipoic acid or its derivatives
RS49520B (en) Antimicrobially active mixtures
ATE301469T1 (en) PHARMACEUTICAL DICLOFENAC COMPOUND BASED ON VITAMIN E, PAPAIN AND HYALURONIDASE
AR022475A1 (en) METHOD FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH CORONARY INTERVENTION.
BR9805195A (en) A new way of administering the etoposide substance
BRPI9908132C1 (en) liquid pharmaceutical composition for oral administration
AR009470A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BACTERIAL STRAINS AND USEFUL IN THE TREATMENT OF DISEASES ASSOCIATED WITH OR CAUSED BY ALTERATIONS IN THE METABOLISM OF BILE ACIDS, AND USE OF THE SAME.
BR9704686A (en) Groups of bacteria and pharmaceutical composition containing such groups, and use thereof to prevent and treat diseases associated with, or caused by altered metabolism of bile acid.